.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Karen Ignagni Calls for Greater Transparency in Pharmaceutical Pricing

November 20, 2014

No entity in healthcare should have a blank check, but that's the current situation with specialty drugs, said Karen Ignagni, president and chief executive officer of America's Health Insurance Plans.

No entity in healthcare should have a blank check, but that’s the current situation with specialty drugs, said Karen Ignagni, president and chief executive officer of America’s Health Insurance Plans.

Her association has been trying to create a dialogue with pharmaceutical companies to find a way for greater transparency in pricing.

“We want to create sustainable innovation,” she said. “There’s no question. Every American wants that. But at the same time we’re not going to be able to create sustainable innovation unless we have such sustainable pricing.”